CYP51A1 and Chagas disease: To broaden the range of CYP51 inhibitors that could be used most efficaciously to treat patients with Chagas Disease, we employed an approach that relies on directly probing the CYP51 active site with diverse compounds to define the chemical and structural space accessible to inhibitors.